tbuckley/cabot-search huggingface dataset:
Abstract 1098: Enhanced AKT-dependent metabolic fitness and antitumor effect of T lymphocytes in lung cancer model
Authors: Sung Eum Kim, Kyoung-Ho Pyo, Sang Bin Lim, Mi Ran Yun, Jae Hwan Kim, Ji Min Lee, Ha Ni Jo, Chun-Feng Xin, Jae Seok Cho, Byoung Chul Cho
Journal: Cancer Research (2019)

Abstract Introduction: PI3K signaling plays a pivotal role in balancing of immune responses. This study is to elucidate the role of PI3K-AKT signaling in regulating T cell metabolic fitness. Methods: PI3K/AKT inhibitors including BKM120 were used to evaluate the contribution of PI3K-AKT signaling on the metabolic fitness of T cell. Glucose metabolism and T cell activity were measured by flow cytometry, IHC, RT-PCR. Oxygen consumption rate (OCR) and extra cellular acidification rate (ECAR) were examined by seahorse. In addition, anti-tumor effects of T cells were evaluated by adaptive transfer in LLC2 tumor bearing mouse. Results: Compare to vehicle, BKM120-treated antigen-specific CD8+ T cells co-cultured with LLC2 cancer cells maintained cytotoxic effects under hypoglycemic and hypoxic conditions. Treatment of BKM120 significantly reduced tumor growth, compared to vehicle in syngeneic models (LLC2, KLN205), whereas it did not affect tumor growth in nude mice, which suggests role of activation of antitumor immunity, augmented by BKM120. Compared to vehicle, BKM120 significantly induced higher infiltration of CD8+ T cells and reduction of Foxp3+ regulatory T cell and CD11b+/Gr-1+ myeloid derived suppressor cells. Intriguingly, increased glucose uptake through overexpression of glucose transporter (GLUT1) was observed upon BKM120 treatment. Glut1 overexpression occurred through the release of feedback inhibition of mTORC2 followed by rebound AKT activation. In addition, glycolysis-related genes (Glut1, Hk, Pgam, Pdk and Pgm) and OCR/ECAR were significantly augmented in BKM120/selective PI3K-delta inhibitor (Idelalisib)-treated group. The enhanced glycolysis via PI3K signaling inhibition was significantly more prominent by Idelalisib, compared to BKM120 or selective PI3K-alpha inhibitor (BYL-719). The antigen-specific T cells pretreated with BKM120 ex vivo exhibited substantially more potent antitumor effects, compared to untreated T cells, in LLC2 tumor-bearing nude mice. Conclusion: PI3K inhibitor, specifically selective PI3K-delta inhibitor, promotes AKT-dependent metabolic fitness of T cells which sustain anti-cancer effects under nutrient/oxygen-deprived tumor microenvironment. These data support a rationale for combination of selective PI3K-delta inhibitor with checkpoint inhibitors anti-PD1 for patient with Lung cancer. Citation Format: Sung Eum Kim, Kyoung-Ho Pyo, Sang Bin Lim, Mi Ran Yun, Jae Hwan Kim, Ji Min Lee, Ha Ni Jo, Chun-Feng Xin, Jae Seok Cho, Byoung Chul Cho. Enhanced AKT-dependent metabolic fitness and antitumor effect of T lymphocytes in lung cancer model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1098.
Glutethimide Not a Dilutant of Heroin
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DLBCL Responds Well to Anti-CD19 CAR Therapy
Journal: Cancer Discovery (2017)

According to an interim analysis of phase II data from a study of the anti-CD19 chimeric antigen receptor T-cell therapy KTE-C19, 76% of 51 patients with diffuse large B-cell lymphoma responded to the treatment; 47% had a complete response. After 3 months, 33% continued to experience a complete response.
"VITAMIN SWEETS"
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE FOLLOWING IS THE OFFICIAL LIST OF DELEGATES GATES AND MEMBERS IN ATTENDANCE UPON THE ANNUAL MEETING OF THE AMERICAN MEDICAL ASSOCIATION IN WASHINGTON, MAY 6-7-8-9, 1884.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases
Authors: Lawrie W. Powell
Journal: Annals of Internal Medicine (2000)

Letters1 February 2000HFE Genotype in Patients with Hemochromatosis and Other Liver DiseasesLawrie W. Powell, MD, PhDLawrie W. Powell, MD, PhDRoyal Brisbane Hospital; Brisbane, Queensland, Australia 4029 (Powell)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-3-200002010-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Franks and Burke (1) have chosen to raise complex issues of diagnostic criteria and population screening strategies in discussing an article that is really quite straightforward and informative to the practicing clinician. Bacon and colleagues (2) showed that the determination of HFE genotype is clinically useful in confirming HFE-associated hemochromatosis and in identifying otherwise unsuspected C282Y homozygotes in patients who have liver disease complicated by iron overload. The authors emphasized that their findings related to patients with liver disease and were not representative of iron overload in the general population. They further stated that “on a population ...References1. Franks AL, Burke W. Will the real hemochromatosis please stand up? [Editorial]. Ann Intern Med. 1999;130:1018-9. LinkGoogle Scholar2. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff KD. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999;130:953-62. LinkGoogle Scholar3. Powell LW, Jazwinska EC, Halliday JW. Primary iron overload.. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. London: Academic Pr; 1994:227-70. Google Scholar4. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-19. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Royal Brisbane Hospital; Brisbane, Queensland, Australia 4029 (Powell) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoWill the Real Hemochromatosis Please Stand Up? Adele L. Franks and Wylie Burke HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Bruce R. Bacon , John K. Olynyk , Elizabeth M. Brunt , Robert S. Britton , and Roger K. Wolff HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Bruce R. Bacon , Robert S. Britton , and John K. Olynyk HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Adele L. Franks and Wylie Burke HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Gordon D. McLaren Metrics 1 February 2000Volume 132, Issue 3Page: 245-246KeywordsGenetic testingHemochromatosisLiver diseasesPatient advocacy Issue Published: 1 February 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Authors: M. Markowitz
Journal: New England Journal of Medicine (1995)

Ritonavir is a potent inhibitor in vitro of human immunodeficiency virus type 1 (HIV-1) protease, which is needed for virions to mature and become infective. We assessed the safety and efficacy of ritonavir in patients with HIV-1 infection.
Numbered Blessings
Authors: Neela K. Sheth
Journal: JAMA (1985)

It isn't easy to enter a hospice room and think of the right words to say. The cheerful "How are you today?" or "Hope you'll feel better tomorrow!" or "See you next week!" all carry loaded meanings and sound hollow, to both the "sayer" and the "listener." My weekly visits as a volunteer started that Thursday evening with Helen, an elderly heavy-set woman with extensive bone metastases from a breast carcinoma treated many years ago. She lay on her bed slightly propped up, breathing heavily and moving her head monotonously from side to side. She alternately moaned and spoke in a soft, guttural tone as I walked to her side. I held her hand and began groping for some useful words to say. Then, gently stroking her hand, I tried to convey to her a nonverbal feeling that I cared about her. I slowly told her that I knew she wasn't
AUTHORS' REPLY
Authors: G W Burdon
Journal: Thorax (1988)

Deoxylaelobin conentratiom in te detection of central cyano_s SIR,-Although not explicitly stated in their article, Dr Geraldine Goss and her associates (March 1988;43:212-3) appear to share with others' the misconception that Lunds- gaard and Van Slyke2 believed cyanosis first could be detected when 5 g/dl reduced haemoglobin was present in the arterial blood.Lundsgaard and Van Slyke wrote, "About 5 grams ofreduced haemoglobin per 100 c.c. ofcapillary blood appear necessary to cause cyanosis.. . 2 They calculated mean capillary unsaturation by averaging the arterial and venous unsaturations.The difference between mean capillary unsaturation and arterial unsaturation would depend on the haemoglobin affinity for oxygen, perfusion ofthe tissue being viewed, and oxygen utilisation by that particular tissue.Since these factors were not reported by Dr Goss and colleagues, their data cannot be used to determine the correctness or incorrectness of the original conclusion of Lundsgaard and Van Slyke.Admittedly, one should have reservations about that early assertion after considering the fact that Lunds- gaard and Van Slyke did not report analyses ofarterial blood specimens on patients-only free flowing peripheral venous specimens had been analysed.It is interesting that reanalysis of Stadie's data from 1919,3 which did involve arterial blood sampling, would lead one to much the same conclusion as was reached by Dr Goss and her associates.None of his five patients without cyanosis had more than 1-3 g/dl arterial unsaturation while 4/27 with cyanosis had values less than 15 g/dl arterial unsaturation.
Leads from the MMWR. Youth suicide--United States, 1970-1980
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 21350: Outcomes With Steroid-Free Maintenance Immunosuppression After Heart Transplant: Results From the United Network for Organ Sharing Registry
Authors: Brian Wayda, Autumn Clemons, Raymond C Givens, Koji Takeda, Hiroo Takayama, Farhana Latif, Susan Restaino, Yoshifumi Naka, A. Reshad Garan, Melana Yuzefpolskaya, Maryjane A Farr, Paolo C Colombo, Veli K Topkara
Journal: Circulation (2017)

Background: Given their adverse effects, there is growing interest in omitting corticosteroids from the initial maintenance immunosuppression (IS) regimen after heart transplant (HT). However, evidence for the efficacy of this strategy is limited. Hypothesis: Steroid-free and steroid-containing maintenance regimens are associated with comparable outcomes following HT. Methods: We included patients who received HT between July 2004 and April 2014 and were discharged on an initial maintenance regimen with both tacrolimus and mycophenolic acid, with or without corticosteroids, and with no other IS medications. Patients with rejection or graft failure (death or re-transplant) prior to discharge were excluded. Survival analyses compared outcomes between steroid-free and steroid-treated patients, including time from discharge to graft failure, hospitalization, and infection and rejection requiring hospitalization. Results: Of 10,080 included patients, 15%, 22%, 11%, and 50% experienced graft failure, infection, rejection, and hospitalization, respectively during the follow-up period (2004 - 2014). Steroid-free regimens were used in 8.2%. Steroid-free patients had lower risks of hospitalization (HR = 0.78, p &lt; 0.0001), infection (HR = 0.56, p &lt; 0.0001), and rejection (HR = 0.66, p = 0.018). There was no significant difference in the risk of graft failure (p = 0.12). Conclusions: Steroid-free and steroid-treated patients have comparable graft survival after HT and differ with respect to other selected outcomes. Further research will determine whether this stems from differences in efficacy or patient mix. A steroid-free strategy is likely optimal for selected patients.
Transactions of the State Medical Society of Wisconsin.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
湿疹的严重程度与进行日常工作的能力相关
Authors: L. Andersen, M.E. Nyeland, F. Nyberg
Journal: British Journal of Dermatology (2020)

特应性皮炎(也称为 AD 或湿疹)是一种常见的皮肤病,见于所有国家。最常见于儿童时期,我们不知道它在成人中究竟有多常见。 本研究报告了法国、德国、英国和美国 AD 成人患者的邮寄问卷调查。研究者来自制药公司利奥制药和阿斯利康制药。 参与者完成了两项问卷调查,其中一项调查涉及其皮肤状况的严重程度,另一项问卷调查记录了其从事工作(就业)能力的任何损害。两者均使用了之前已成功测试并正确使用的问卷。 1098 名被调查者被发现患有中重度湿疹。研究发现,如果他们的工作能力降低(即无法像以前一样工作),这与 AD 的严重程度直接相关。 例如,对于 AD 导致的总体工作障碍,轻度 AD 被调查者报告平均每周 2.4 小时的潜在工作效率丧失,中度 AD 被调查者为 9.6 小时,重度 AD 被调查者为 19.0 小时。 在不同国家,受影响的受试者进行日常活动能力的总体损害不同;例如,在中度 AD 受试者中,所有参与者的降低率为 26.7%,生活在欧洲的参与者为 34.0%,美国参与者为 15.2%。 这种差异被认为是由于不同国家在获得社会和经济支持方面的差异造成的。 研究证实,中度或重度特应性皮炎会对该疾病成人进行正常就业的能力产生显著和不利影响。 本摘要涉及研究:在法国、德国、英国和美国,特应性皮炎严重程度的增加与特应性皮炎成人患者工作效率的负面影响相关。
American Journal of Clinical Pathology, Indianapolis
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Resuscitation Service
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE GOVERNOR OF CALIFORNIA ON THE PLAGUE.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inside Front Cover Image, Volume 40, Issue 5
Authors: Radomir Juza, Premysl Vlcek, Eva Mezeiova, Kamil Musilek, Ondrej Soukup, Jan Korabecny
Journal: Medicinal Research Reviews (2020)

The inside front cover image is based on the Review Article Recent Advances with 5-HT3 Modulators for Neuropsychiatric and Gastrointestinal Disorders by Jan Korabecny, Ondrej Soukup, Kamil Musilek et al., https://doi.org/10.1002/med.21666.